News

Actemra successfully met its primary endpoint in patients with moderate to severe rheumatoid arthritis (RA) who failed to respond to anti-tumor necrosis factor treatments (anti-TNFs). The trial –

The worldwide exclusive license deal includes an upfront fee and milestone payments as well as royalties on future sales. A novel drug technology to treat Alzheimer’s disease developed

Suffers of mesothelioma, a lung cancer linked with asbestos exposure, have welcomed the government’s U-turn. The National Institute for Health and Clinical Excellence (Nice) reversed its decision after

As such, DCVax-Brain is the first commercially available therapeutic vaccine for such cancers, according to Biotherapeutics, which intends to begin making the product available to patients in Q3

Rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head comparison with Sanofi-Aventis’ Lovenox, known generically as enoxaparin,

Top-line data from the first of two phase III clinical studies to assess the safety and efficacy of tolevamer liquid, a polymer therapy for patients with Clostridium difficile

In the randomized, six week, placebo-controlled trials involving a total of 1,551 subjects, PreHistin did not achieve statistically significant differences from placebo in the primary measure of efficacy,

Sanofi says that the study showed the benefit of extended prophylaxis in acutely ill medical patients with reduced mobility by demonstrating the superiority of a five week course

The alliance will initially cover four therapeutic areas: oncology, respiratory diseases, metabolic diseases and certain liver diseases. Alnylam and Roche also will collaborate on RNAi drug discovery for